
    
      Primary objective

      - To evaluate adherence to oral anti-cancer therapies at 3 months

      Secondary objectives

        -  To evaluate the adherence to 3 months according to the age of the patients (less than 75
           years versus 75 years and more)

        -  Evaluate compliance at 1 and 2 months

        -  Evaluate toxicity at 1, 2 and 3 months according to compliance according to criteria
           CTCAE 4.03.

        -  Evaluate response to treatment at 3 months based on adherence

        -  Evaluate the factors associated with adherence and describe the reasons for
           non-adherence.
    
  